A legal entity created on a voluntary basis and engaged in a certain business, company can operate in different market and counties. A company size is measured on the basis of its market value, sales, assets or profits. As a rule, companies are represented by the following types: be private, public, government, unlimited, foreign, producer, to name a few. Typical departments found in almost any company comprise but are not limited to production, customer services, marketing, human resources, finance, to name a few.
Exxon Mobil, JPMorgan Chase, Shell, Apple, Royal Dutch Shell and Toyota Motor are amidst the globe’s largest and most influential companies, with most of them active the world over.
This Catalogue’s research reports cover companies involved in various business activities, be it production, sales, marketing, etc. The reports contain information on companies’ activities, historical development, key executives, departments, product offerings. SWOT analyses, data on market share, marketing strategies, the most recent activities within the industry, acquisitions, strategic partnerships and alliances are included in the research reports.
Publications found:
193,061
Sort by:
BIOGEN IDEC - Hold On - After TECFIDERA Array of Approvals Yet to Come!
US$ 140.00
... -release capsule of dimethyl fumerate) with a ‘clean’ label should seal Biogen Idec (BIIB)’s supremacy in the MS space. We expect TECFIDERA to become the ... our report released on 28th March, 2013 on BIIB titled, “Hold On - After TECFIDERA Array of Approvals Yet to Come!” Companies mentioned BIIB, BIOGEN IDEC
March 2013
6 pages
TRIUS THERAPEUTICS - Partnering or Buy Out = Upside
US$ 90.00
... and Skin Structure Infections – ABSSSI; PhII, CAP/HAP/Bacteremia, partnered with Bayer for Asian, LA and ME rights) from 2nd pivotal ... , please read our initiation report released on 26th March, 2013 on Trius (TSRX) titled “Partnering or Buy Out = Upside” Companies mentioned Trius Therapeutics
March 2013
4 pages
Astellas, Acofide: Japanese Approval Raises Global Hopes!
US$ 90.00
... approval for Acofide in Japan (Acotiamide /Z-338, functional dyspepsia, jointly developed by Astellas and Zeria in Japan). Acofide is the first drug to be approved ... for Functional Dyspepsia (under Rome III criteria) and addresses a huge unmet need – it is estimated that over a quarter of Japanese ...
March 2013
3 pages
World's 7 Leading Truck-Makers - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - 2013 - Daimler, Volvo, MAN, Scania, PACCAR, Navistar, Iveco
US$ 1,275.00
... as well as analysis of the Key Strategies & Plans of these 7 key Global Truck-Making companies against the backdrop of an evolving industry landscape; marked by ... into key Business Strategies & Plans being pursued by each key Truck-maker Gaining a Strategic Perspective on the Business & Strategic Outlook for ...
March 2013
World's 7 Leading Construction Equipment Manufacturers - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - 2013 - Caterpillar, Komatsu, Volvo, CNH, Hitachi, Sandvik, Terex
US$ 1,275.00
... as well as analysis of the Key Strategies & Plans of these 7 key Global Construction Equipment manufacturing companies against the backdrop of an evolving industry landscape; ... the slowing down of mining activity, the demand for mining equipment, too, has also been impacted significantly. Thus, with declining ...
March 2013
ACORDA - Building Confidence Beyond AMPYRA!
US$ 140.00
Acorda Therapeutics (ACOR) reported 4Q/FY12 results with a decent growth in sales ... label expansion of AMPYRA (POC data in 2Q13) and pipeline beyond AMPYRA could lead to the next driver to the stock. Successful ... our report released on 15th February 2013 on ACOR titled “Building Confidence Beyond AMPYRA!”
February 2013
3 pages
Globus Spirits LTD.- COMPANY Information & SWOT Analysis
US$ 100.00
... bulk litres (BL) per annum. IS Advisors takes you through the Company information and a detailed SWOT Analysis of the company in this report. The ... the company, in the form of SWOT framework Examines and identifies key information and issues about company for business intelligence requirements Financial ...
February 2013
41 pages
Radico Khaitan LTD.- COMPANY Information & SWOT Analysis
US$ 100.00
... industrial alcohols, while also launching premium liquor products. Established in 1943, Radico Khaitan is India’s oldest alcoholic beverage company. It had entered the ... and Industrial Liquor. IS Advisors takes you through the Company information and a detailed SWOT Analysis of the company in this report. The ...
February 2013
35 pages
United Breweries LTD.- COMPANY Information & SWOT Analysis
US$ 100.00
EXECUTIVE SUMMARY United Breweries (UBL) incorporated in 1999, is a flagship company of UB Group. The company is engaged in manufacturing and marketing of beer. UBL has an association with brewing dating back over nine decades, starting with 5 breweries in South India in 1915. From bullock cart-loaded ...
February 2013
39 pages
United Spirits LTD.- COMPANY Information & SWOT Analysis
US$ 100.00
EXECUTIVE SUMMARY United Spirits (USL) is the leading alcoholic beverages producer and distributor in India with a market share of ~53%. It has the largest ... cases a year) in its portfolio. IS Advisors takes you through the Company information and a detailed SWOT Analysis of the company in this report. The ...
February 2013
35 pages
CURIS- Time to Assess Value Beyond Erivedge!
US$ 140.00
... to bring a change in treatment paradigm of hematological malignancies (CLL, iNHL, ALL). Curis’s (CRIS) pipeline consists of a marketed drug Erivedge (L in US, R in EU/other, vismodegib, HedgeHog ... read our report released on 11th February. 2013 on CRIS titled “Time to Assess Value Beyond Erivedge!”
February 2013
7 pages
ISIS Pharma - Picture Beyond KYNAMRO - Targeting Other Niche Indications
US$ 140.00
... test that all antisense/ RNAi focused companies have to pass. ISIS has a robust cash position, valuable IP assets, and success of a few ... in the current pipeline could accelerate the transformation from a discovery to a pharma company and help it to grow beyond KYNAMRO.
January 2013
7 pages
Competitive Intelligence: Leading Specialty Chemicals Companies Strategic Directions
US$ 2,280.00
This new report from Venture Planning Group provides strategic directions of leading specialty chemicals companies. The report presents insightful strategic assessments, including: Specific business, new product development and marketing strategies. Strengths and weaknesses. Anticipated acquisitions, joint ...
January 2013
56 pages
Competitive Intelligence: Leading Specialty Chemicals Companies Marketing Tactics
US$ 1,480.00
This new report from Venture Planning Group provides marketing tactics of leading specialty chemicals companies. The analysis presents: Major promotional strategies. Distribution approaches. Product service and support. The companies analyzed in the report are AkzoNobel, BASF, Ciba, Clariant, Evonik, ICI, ...
January 2013
35 pages
ASTRAZENECA - Tremendous pressure - Messiah to be found
US$ 90.00
AZN reported its 4Q-2102 financial results, revenue declined by 15% while core EPS was up by 1% driven by one time tax benefits and lower operating costs. For 2013, the company has guided mid to high single digit decline in revenue, while core EPS should decline faster than revenue due to higher operating ...
January 2013
2 pages
LUPIN, Quarterly Outperformance Driven by US, Tough Year Ahead
US$ 140.00
Lupin’s Q3FY13 result was higher than our estimates largely on account of ... are well entrenched and customers remain greatly brand loyal. Lupin’s earnings will also remain exposed to an appreciating INR. We increase our ...
January 2013
7 pages
SUNPHARMA - Acquisitions to drive the next Growth Wave
US$ 140.00
... this will take time. Leveraging Balance sheet for Acquisition Consolidation of recent acquisitions (URL and DUSA) as well as management’s quest for new ... in US. Management has commented that Sun Pharma will continue to seek acquisitions in US (focus on Derma) and other emerging markets with small to medium ...
January 2013
7 pages
CIPLA - Growth to Slow Down, Tough Time Ahead
US$ 140.00
... is looking to acquire front end. Going forward in FY14 we expect revenue growth to remain modest (8-9%) due to (1) high base of FY13 (2) dearth of ... do not remain enthused about Cipla’s inhaler opportunity in Europe as it has lost the first mover advantage. Modest growth in revenue (8-9%), Lower EBITDA margins ...
January 2013
6 pages
BMW Group - Key Business & Growth Strategies, Plans, SWOT, Trends & Outlook for 2013
US$ 325.00
... Report Analyzes & provides Insights into the Key Business & Growth Strategies, Plans & Business Outlook for BMW Group for the year 2013 ... areas for Potential Strategic Adjustments, Changes & Realignment Gaining access to Key Industry as well as Market Trends & Insights Analysis of Forces Driving & restraining ...
December 2012
23 pages
CLAAS Group - Key Business & Growth Strategies, Plans, SWOT, Trends & Outlook for 2013
US$ 325.00
... Analyzes & provides Insights into the Key Business & Growth Strategies, Plans & Business Outlook for CLAAS Group for the year 2013 ... areas for Potential Strategic Adjustments, Changes & Realignment Gaining access to Key Industry as well as Market Trends & Insights Analysis of Forces Driving & restraining ...
December 2012
23 pages
Daimler AG - Key Business & Growth Strategies, Plans, SWOT, Trends & Outlook for 2013
US$ 325.00
... Analyzes & provides Insights into the Key Business & Growth Strategies, Plans & Business Outlook for %li%Daimler AG for the year 2013 based on ... Trucking Industry or any of these companies & will be especially useful for key decision makers, top management of companies, suppliers, vendors, current & potential ...
December 2012
23 pages
EADS N.V. - Key Business & Growth Strategies, Plans, SWOT, Trends & Outlook for 2013
US$ 325.00
... Analyzes & provides Insights into the Key Business & Growth Strategies, Plans & Business Outlook for EADS N.V. for the year 2013 based ... areas for Potential Strategic Adjustments, Changes & Realignment Gaining access to Key Industry as well as Market Trends & Insights Analysis of Forces Driving & restraining ...
December 2012
23 pages
Embraer S.A.- Key Business & Growth Strategies, Plans, SWOT, Trends & Outlook for 2013
US$ 325.00
... Report Analyzes & provides Insights into the Key Business & Growth Strategies, Plans & Business Outlook for Embraer S.A. for the year 2013 based ... Aviation Industry or any of these companies & will be especially useful for key decision makers, top management of companies, suppliers, vendors, current & potential ...
December 2012
23 pages
Iveco S.p.A. - Key Business & Growth Strategies, Plans, SWOT, Trends & Outlook for 2013
US$ 325.00
... Analyzes & provides Insights into the Key Business & Growth Strategies, Plans & Business Outlook for Iveco S.p.A. for the year 2013 based on ... Trucking Industry or any of these companies & will be especially useful for key decision makers, top management of companies, suppliers, vendors, current & potential ...
December 2012
23 pages
Komatsu Ltd. - Key Business & Growth Strategies, Plans, SWOT, Trends & Outlook for 2013
US$ 325.00
... Analyzes & provides Insights into the Key Business & Growth Strategies, Plans & Business Outlook for Komatsu Ltd. for the year 2013 ... areas for Potential Strategic Adjustments, Changes & Realignment Gaining access to Key Industry as well as Market Trends & Insights Analysis of Forces Driving & restraining ...
December 2012
23 pages
